O'Shaughnessy Asset Management’s TG Therapeutics TGTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$366K	Sell	6,666 -719	-10%	-$29.4K	﹤0.01%	1742
2026 Q1	$245K	Buy	+7,385	New	+$220K	﹤0.01%	1898
2025 Q4	–	Sell	-6,582	Closed	-$238K	–	2745
2025 Q3	$238K	Sell	6,582 -1,800	-21%	-$59.3K	﹤0.01%	1876
2025 Q2	$302K	Sell	8,382 -847	-9%	-$31.5K	﹤0.01%	1625
2025 Q1	$364K	Buy	9,229 +612	+7%	+$20.6K	﹤0.01%	1472
2024 Q4	$259K	Buy	+8,617	New	+$247K	﹤0.01%	1614
2021 Q4	–	Sell	-3,490	Closed	-$116K	–	2369
2021 Q3	$116K	Sell	3,490 -2,738	-44%	-$84.7K	﹤0.01%	1315
2021 Q2	$241K	Buy	6,228 +21	+0.3%	+$825	﹤0.01%	940
2021 Q1	$299K	Buy	+6,207	New	+$298K	0.01%	779

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

O'Shaughnessy Asset Management's TGTX Position: Q2 2026 in Review

O'Shaughnessy Asset Management reduced its TG Therapeutics (TGTX) stake by 9.7% in Q2 2026, selling an estimated $29.4K and leaving 6,666 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

O'Shaughnessy Asset Management first reported a position in TGTX in Q1 2021 and has held it in 9 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

O'Shaughnessy Asset Management held 6,666 shares of TG Therapeutics worth $366K as of Q2 2026.
O'Shaughnessy Asset Management sold 719 TG Therapeutics shares in Q2 2026, an estimated $29.4K.
TG Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1742 holding.
O'Shaughnessy Asset Management first reported a position in TG Therapeutics in Q1 2021 and has held it in 9 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.